• / Free eNewsletters & Magazine
  • / My Account
Home>Have Emerging Markets Gotten Oversold?

Have Emerging Markets Gotten Oversold?

Morningstar Articles

Mon, 26 Aug 2013

Merck MRK announced Tuesday that Januvia for Type 2 diabetes received Food and Drug Administration approval. While we think Januvia is an important advance in diabetes treatment, we're not changing our fair value estimate for Merck, as we had already

Related Videos

  1. Our 2014 Big Pharma Pipeline Rankings: Who Came Out on Top?

    Merck's reinvigorated pipeline and Sanofi's minimal patent-loss exposure placed them atop our rankings this year, while GlaxoSmithKline joined Pfizer toward the bottom.

  2. Retirees: Learn From the Recent Bond Turbulence

    How investors can use the recent interest-rate-driven disruption as a stress-test for their portfolios. Plus, a new retirement income tool and some good news on prescription-drug costs.

  3. Investors Still Exiting Bonds

    August saw continued big bond-fund redemptions and a divergence of institutional and individual investor flows in emerging - markets funds.

©2017 Morningstar Advisor. All right reserved.